Business Management Articles

FDA Approves Reduced Dose of Cabazitaxel for mCRPC
The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.
Expert Discusses Approval of First CAR T-Cell Therapy
James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.
FDA Halts Enrollment on 3 Nivolumab Myeloma Trials
The FDA has placed partial clinical holds on 3 trials assessing nivolumab (Opdivo)-based combinations in patients with relapsed/refractory multiple myeloma.
Proposed Changes to 340B May Curb Hospital Abuses
Outpatient branded drug sales in the 340B Drug Pricing Program now amount to almost 8% of the total market, well up from 5.4% in 2012.
Novartis’ just-approved chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel is going to be introduced on the market at a price of $475,000 for a single infusion, an amount that is within the range anticipated by oncologists.
Palliative Care Consultations Significantly Reduce Healthcare Utilization
End-of-life palliative care consultations can significantly reduce healthcare utilization, according to a broad-based population study published in the Journal of Oncology Practice.
It is not far-fetched to believe that, one day soon, automated systems will be able to obtain payer approval for therapies without any human involvement.
Despite all the excitement and anticipation, there is a growing anxiety among payers and providers regarding the cost of CAR T cells.
Investigators at Cota, a New York medical data analytics company, are taking further strides toward putting their growing knowledge of variance in care to work in the clinical setting.
The FDA has approved inotuzumab ozogamicin for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Publication Bottom Border
Border Publication